Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PersoMed-I: Personalized Risk-Adapted Therapy in Post-Pubertal Patients with Newly Diagnosed Medulloblastoma
2020-003063-26Phase 2Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Oct 2021
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of sonidegib in medulloblastoma (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression-free survival in SHH-activated subgroup. Started Oct 2021; status: terminated.
02
Drugs
sonidegib
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on 2020-003063-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003063-26.